BCPP is leading the development of a first-ever, comprehensive breast cancer primary prevention plan for California. With a strong foundation of science and input from many stakeholders, including academics, government regulators, non-profit organizations and impacted communities; we will create a policy agenda to reduce breast cancer risk factors in California. Yet the majority of women who are diagnosed with breast cancer have none of the risk factors most commonly associated with the disease. This begs the question why, while it also raises further questions about how we reduce risk for the disease at the individual, community, and societal levels. The California primary prevention plan seeks to explore the full range of prevention opportunities that can contribute to a statewide effort to reduce the incidence of breast cancer.
Cancer Drug Implementation Advisory Committee (CDIAC)
Advisory Groups | Cancer Australia
The first European conference on risk-stratified prevention and early detection of breast cancer was held from 26 to 28 June in Austria. The main objective was to pool knowledge and set actions towards implementation of risk-based breast cancer prevention and We are proud to share these recent relevant publications by the teams involved in MyPeBS consortium Manchester team highlighted for the first time, the ability of a risk model Tyrer Cuzick including density and SNPs not only to predict for breast cancer risk, but Some bits of the normal genetic material DNA differs between one person and another: they are known as single nucleotide polymorphisms or SNPs. Different combinations of these SNPs are associated
Cancer Australia acknowledges the significant input and valuable advice extended to the agency by strategic and tumour specific advisory groups. Group members represent a broad range of expertise, experiences and sectors, including policy, research, health promotion and communication. Consumers are represented on all Cancer Australia Advisory Groups.
He is a researcher in the field of health services research, health policy and health systems research, member of the Scientific Committee of EUPHA, member of Academy Health, member of the Slovenian Preventive Medicine Society - currently also member of its Board and a member of the Health Council of the Ministry of Health of Slovenia. He acts as a reviewer of several scientific journals and of projects submitted for funding to the European Commission. Jean-Pierre Armand is a medical oncologist and Senior Consultant at Institute Gustave Roussy and Institute Curie in Paris with a major interest in early drug development and personalised medicine.